Clinical Trials Logo

Sea Sickness clinical trials

View clinical trials related to Sea Sickness.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05886660 Recruiting - Motion Sickness Clinical Trials

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

Start date: January 21, 2022
Phase: Phase 2
Study type: Interventional

The primary specific aim is to evaluate the use of intranasal scopolamine gel and sensory augmentation as an integrated countermeasure to mitigate motion sickness and enhance sensorimotor performance. The proposed intranasal scopolamine gel formulation (Defender Pharmaceuticals, Inc.) offers a safe non-invasive method to self-administer with a rapid onset of action. This study involves a comparison of motion sickness outcome measures when administering intranasal scopolamine gel versus placebo (Aim 1a), and then when administering intranasal scopolamine gel versus placebo with a sensory augmentation belt (Aim 1b).